Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
Healthcare
$15.78 -0.39%
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
52W Low $7.91High $28.72
Volume 1.07M
Average 1.17M
Balance Sheet
Inspect the capital base behind the business.
Assets
$1.14B
FY 2025 · Annual
-1.0% YoYLiabilities
$508.00M
FY 2025 · Annual
-23.6% YoYEquity
$631.00M
FY 2025 · Annual
+30.1% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 147.91M | 206M | 127M | 150M | 222M |
| Short-term Investments | 351.39M | 803M | 632M | 828M | 759M |
| Net Receivables | 746.82M | 43M | 42M | 25M | 16M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 14.72M | 14M | 30M | 13M | 10M |
| Total Current Assets | 1.26B | 1.07B | 831M | 1.02B | 1.01B |
| Property, Plant & Equipment (Net) | 137.42M | 135M | 51M | 47M | 40M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 185M | 134M | 107M | 14M | 29M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.73M | 10M | 106M | 73M | 63M |
| Total Non-current Assets | 330.15M | 279M | 264M | 134M | 132M |
| Total Assets | 1.59B | 1.35B | 1.1B | 1.15B | 1.14B |
| Account Payables | 10.26M | 20M | 17M | 18M | 42M |
| Short-term Debt | 5.1M | 3M | 0 | 0 | 0 |
| Tax Payables | 1.82M | 0 | 0 | 1M | 0 |
| Deferred Revenue | 102M | 97M | 91M | 85M | 35M |
| Other Current Liabilities | 30.26M | 48M | 39M | 14M | 18M |
| Total Current Liabilities | 166.08M | 193M | 184M | 226M | 231M |
| Long-term Debt | 0 | 0 | 0 | 48M | 99M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 462.22M | 355M | 307M | 234M | 43M |
| Other Non-current Liabilities | 5.26M | 23M | 142M | 157M | 135M |
| Total Non-current Liabilities | 584.36M | 495M | 449M | 439M | 277M |
| Total Liabilities | 750.45M | 688M | 633M | 665M | 508M |
| Common Stock | 7K | 1.21B | 1.31B | 1.62B | 2.12B |
| Retained Earnings | (275.35M) | (542M) | (849M) | (1.13B) | (1.49B) |
| Accumulated OCI | (1.26M) | (7M) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 841.45M | 657M | 462M | 485M | 631M |
| Total Debt | 121.99M | 120M | 11M | 60M | 112M |
| Net Debt | (25.93M) | (86M) | (116M) | (90M) | (110M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $150.0M |
| Short-term Investments | $552.0M |
| Receivables | $36.0M |
| Other Current | $18.0M |
| Total Current Assets | $756.0M |
| PP&E (Net) | $36.0M |
| Long-term Investments | $73.0M |
| Other Non-current | $59.0M |
| Total Non-current Assets | $168.0M |
| Total Assets | $924.0M |
Analysis
Selected assets total $924.0M for Latest. The largest visible component is Short-term Investments at $552.0M, about 59.7% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 8-K | Current report | Oct 23, 2026 | |
| 424B5 | 424B5 filing | Oct 22, 2026 | |
| 8-K | Current report | Oct 21, 2026 |
How much cash does RCUS have?
Arcus Biosciences, Inc. (RCUS) reported $222.00M in cash and equivalents in fiscal 2025.
How much debt does RCUS carry?
Arcus Biosciences, Inc. (RCUS) reported $112.00M of total debt, with net debt of -$110.00M.
Continue the stock analysis
Jump to another research area for this company.